Martina Zimovjanova

List of Publications by Year
in descending order

9 papers	1,846 citations	1478505 6 h-index	1588992 8 g-index
9 all docs	9 docs citations	9 times ranked	3075 citing authors

#	Article	IF	Citations
1	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet, The, 2013, 381, 805-816.	13.7	1,664
2	Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. International Journal of Cancer, 2019, 145, 1782-1797.	5.1	62
3	The PALB2 Gene Is a Strong Candidate for Clinical Testing in BRCA1- and BRCA2-Negative Hereditary Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2323-2332.	2.5	42
4	Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene. Breast Cancer Research and Treatment, 2010, 124, 337-347.	2.5	33
5	Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers. Cancers, 2019, 11, 738.	3.7	22
6	Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy â€" results from an expanded access programme. European Journal of Cancer, Supplement, 2004, 2, 132-133.	2.2	11
7	Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers. Aesthetic Plastic Surgery, 2022, 46, 706-711.	0.9	7
8	4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study. Bulletin Du Cancer, 2004, 91, E279-83.	1.6	5
9	Abstract P3-14-01: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis. , 2020, , .		0